CN111956790A - 用于增加人体胶原蛋白及网状纤维的药物的制备方法 - Google Patents
用于增加人体胶原蛋白及网状纤维的药物的制备方法 Download PDFInfo
- Publication number
- CN111956790A CN111956790A CN202010828864.8A CN202010828864A CN111956790A CN 111956790 A CN111956790 A CN 111956790A CN 202010828864 A CN202010828864 A CN 202010828864A CN 111956790 A CN111956790 A CN 111956790A
- Authority
- CN
- China
- Prior art keywords
- parts
- steps
- green tea
- medicine
- following
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 102000008186 Collagen Human genes 0.000 title claims abstract description 38
- 108010035532 Collagen Proteins 0.000 title claims abstract description 38
- 229920001436 collagen Polymers 0.000 title claims abstract description 38
- 108010081750 Reticulin Proteins 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 28
- 244000269722 Thea sinensis Species 0.000 claims abstract description 26
- 235000009569 green tea Nutrition 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000243 solution Substances 0.000 claims abstract description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 16
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 8
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 8
- 229930091371 Fructose Natural products 0.000 claims abstract description 8
- 239000005715 Fructose Substances 0.000 claims abstract description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 8
- 239000004471 Glycine Substances 0.000 claims abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 8
- 244000299461 Theobroma cacao Species 0.000 claims abstract description 8
- 240000008042 Zea mays Species 0.000 claims abstract description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 8
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 8
- 235000005822 corn Nutrition 0.000 claims abstract description 8
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 8
- 239000011259 mixed solution Substances 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 239000006188 syrup Substances 0.000 claims abstract description 8
- 235000020357 syrup Nutrition 0.000 claims abstract description 8
- VLCLHFYFMCKBRP-UHFFFAOYSA-N tricalcium;diborate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]B([O-])[O-].[O-]B([O-])[O-] VLCLHFYFMCKBRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000628997 Flos Species 0.000 claims abstract description 4
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 claims abstract description 4
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 claims abstract description 4
- 235000001046 cacaotero Nutrition 0.000 claims abstract description 4
- 239000000758 substrate Substances 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 6
- 239000001354 calcium citrate Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 6
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 4
- 240000000249 Morus alba Species 0.000 claims description 4
- 235000008708 Morus alba Nutrition 0.000 claims description 4
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 244000276331 Citrus maxima Species 0.000 claims description 3
- 235000001759 Citrus maxima Nutrition 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000011033 desalting Methods 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 235000015205 orange juice Nutrition 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000008247 solid mixture Substances 0.000 claims description 3
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 5
- 241000723353 Chrysanthemum Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000003648 hair appearance Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000037257 muscle growth Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- -1 tissue engineering Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/02—Preparation of carboxylic acids or their salts, halides or anhydrides from salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
Abstract
本发明公开了用于增加人体胶原蛋白及网状纤维的药物的制备方法,包括如下步骤,步骤一:以甘氨酸和胶原蛋白肽为基底原料,依次加入玉米糖浆,二甲基砜,硫酸软骨素和果糖硼酸钙进行预混合,混合时长为4‑6min,得到混合物;步骤二:对上述混合物再依次加入菊花提取物,可可干籽提取物,桑叶提取物、绿茶精华和水,继续搅拌,搅拌时长为8‑12min,得到混合溶液;步骤三:对步骤二中的混合溶液继续加入透明质酸,柠檬酸和钠,搅拌后得到药物溶液。本发明方法制备的增加人体胶原蛋白及网状纤维的药物胶原蛋白含量丰富,添加了多类人体所需的辅助要素,对于身体的改善效果明显,适合广泛推广和各类人群的服用。
Description
技术领域
本发明涉及药物制造技术领域,特别涉及用于增加人体胶原蛋白及网状纤维的药物的制备方法。
背景技术
胶原蛋白是生物高分子,动物结缔组织中的主要成分,也是哺乳动物体内含量最多、分布最广的功能性蛋白,占蛋白质总量的25%~30%,某些生物体甚至高达80%以上胶原蛋白种类较多,常见类型为Ⅰ型、Ⅱ型、Ⅲ型、Ⅴ型和Ⅺ型,胶原蛋白因具有良好的生物相容性、可生物降解性以及生物活性,因此在食品、医药、组织工程、化妆品等领域获得广泛的应用;
目前对于增加人体胶原蛋白及网状纤维的药物使用效果不一,其使用针对性不强,对于服用者的身体改善效果不明显,例如发质状况、骨骼状况和肌肉状况等,长期推广使用的适应性不足。
发明内容
本发明的主要目的在于提供用于增加人体胶原蛋白及网状纤维的药物,该制备方法制备的增加人体胶原蛋白及网状纤维的药物对于人体状况的改善效果明显,可以有效解决背景技术中的问题。
为实现上述目的,本发明采取的技术方案为:用于增加人体胶原蛋白及网状纤维的药物的制备方法,包括如下步骤:
步骤一:以甘氨酸和胶原蛋白肽为基底原料,依次加入玉米糖浆,二甲基砜,硫酸软骨素和果糖硼酸钙进行预混合,混合时长为4-6min,得到混合物;
步骤二:对上述混合物再依次加入菊花提取物,可可干籽提取物,桑叶提取物、绿茶精华和水,继续搅拌,搅拌时长为8-12min,得到混合溶液;
步骤三:对步骤二中的混合溶液继续加入透明质酸,柠檬酸和钠,搅拌后得到药物溶液;
步骤四:对上述药物溶液进行入模压制,得到所需药物规格和形状;
步骤五:对上述入模的药物溶液进行干燥,干燥温度为75-80℃,干燥时长为25-35min,使其含水率不高于5%;
步骤六:脱模包装后得到所需药物。
优选的,步骤一中各原料的使用含量按重量份计,包括甘氨酸30份,胶原蛋白肽20份,玉米糖浆8份,二甲基砜8份,硫酸软骨素10份和果糖硼酸钙12份。
优选地,步骤二中各原料的使用含量按重量份计,包括菊花提取物2份,可可干籽提取物3份,桑叶提取物3份和绿茶精华2份,其余组分为水。
优选地,步骤三中各原料的使用含量按重量份计,包括透明质酸3份,柠檬酸2份和钠1份。
优选地,所述绿茶精华的制备方法为:
步骤一:取200g绿茶茶叶,放入清水浸泡,浸泡时长为10-20min,然后取出自然晾干;
步骤二:对上述晾干的绿茶茶叶进行碾碎,得到绿茶末;
步骤三:将步骤二中的绿茶末放入索氏提取器,再次加入1kg清水,将清水煮沸,并在85-90℃的状态下保持1.5h,待水分蒸发,得到含固态混合物;
步骤四:对上述步骤的含固态混合物进行过滤,即得到所需绿茶精华。
优选地,所述柠檬酸的制备方法为:
步骤一:取橙汁和柚汁共50g,将其加热至75-85℃,然后静置10-15min;
步骤二:对上述溶液加入15g碳酸钙乳浆,并再次加热至100℃,持续然后静置沉淀15-25min,得到柠檬酸钙;
步骤三:对步骤二得到的柠檬酸钙进行除盐并酸解脱色,使用清水加热清洗,清洗时长为25-30min,清洗温度为85-90℃,然后加入40%浓度硫酸,并继续加热至100℃,加热时长为8-12min;
步骤五:对上述步骤的溶液加入1-2%含量的活性炭混合,持续反应15-25min,并进行干燥5-8min,即得到无色清液;
步骤六:对上述无色清液进行浓缩,使其呈固态,静置后得到柠檬酸结晶;
步骤七:对上述柠檬酸结晶进行干燥,干燥时长为25-35min,继而得到所需柠檬酸。
本发明具有如下有益效果:
本发明方法制备的增加人体胶原蛋白及网状纤维的药物胶原蛋白含量丰富,并且添加了多类人体所需的辅助要素,对于身体的改善效果明显,适合广泛推广和各类人群的服用。
本发明方法制备的增加人体胶原蛋白及网状纤维的药物在对人体发质状况、骨骼状况和肌肉状况等方面使用效果优势明显,能够有效改善发质,提升光泽,并且提升骨骼韧性,抗衰老,同时能够促进生长激素分泌以及肌肉生长,有利于身材的保持。
本发明方法制备的增加人体胶原蛋白及网状纤维的药物服用无毒副作用,安全性高。
当然,实施本发明的任一产品并不一定需要同时达到以上所述的所有优点。
具体实施方式
下面将对本实用发明例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
实施例1
用于增加人体胶原蛋白及网状纤维的药物的制备方法,包括如下步骤:
步骤一:以甘氨酸和胶原蛋白肽为基底原料,依次加入玉米糖浆,二甲基砜,硫酸软骨素和果糖硼酸钙进行预混合,混合时长为4-6min,得到混合物;
步骤二:对上述混合物再依次加入菊花提取物,可可干籽提取物,桑叶提取物、绿茶精华和水,继续搅拌,搅拌时长为8-12min,得到混合溶液;
步骤三:对步骤二中的混合溶液继续加入透明质酸,柠檬酸和钠,搅拌后得到药物溶液;
步骤四:对上述药物溶液进行入模压制,得到所需药物规格和形状;
步骤五:对上述入模的药物溶液进行干燥,干燥温度为75-80℃,干燥时长为25-35min,使其含水率不高于5%;
步骤六:脱模包装后得到所需药物。
其中,步骤一中各原料的使用含量按重量份计,包括甘氨酸30份,胶原蛋白肽20份,玉米糖浆8份,二甲基砜8份,硫酸软骨素10份和果糖硼酸钙12份。
其中,步骤二中各原料的使用含量按重量份计,包括菊花提取物2份,可可干籽提取物3份,桑叶提取物3份和绿茶精华2份,其余组分为水。
其中,步骤三中各原料的使用含量按重量份计,包括透明质酸3份,柠檬酸2份和钠1份。
其中,绿茶精华的制备方法为:
步骤一:取200g绿茶茶叶,放入清水浸泡,浸泡时长为10-20min,然后取出自然晾干;
步骤二:对上述晾干的绿茶茶叶进行碾碎,得到绿茶末;
步骤三:将步骤二中的绿茶末放入索氏提取器,再次加入1kg清水,将清水煮沸,并在85-90℃的状态下保持1.5h,待水分蒸发,得到含固态混合物;
步骤四:对上述步骤的含固态混合物进行过滤,即得到所需绿茶精华。
其中,柠檬酸的制备方法为:
步骤一:取橙汁和柚汁共50g,将其加热至75-85℃,然后静置10-15min;
步骤二:对上述溶液加入15g碳酸钙乳浆,并再次加热至100℃,持续然后静置沉淀15-25min,得到柠檬酸钙;
步骤三:对步骤二得到的柠檬酸钙进行除盐并酸解脱色,使用清水加热清洗,清洗时长为25-30min,清洗温度为85-90℃,然后加入40%浓度硫酸,并继续加热至100℃,加热时长为8-12min;
步骤五:对上述步骤的溶液加入1-2%含量的活性炭混合,持续反应15-25min,并进行干燥5-8min,即得到无色清液;
步骤六:对上述无色清液进行浓缩,使其呈固态,静置后得到柠檬酸结晶;
步骤七:对上述柠檬酸结晶进行干燥,干燥时长为25-35min,继而得到所需柠檬酸。
实施例2
针对于本发明方法制备的增加人体胶原蛋白及网状纤维的药物的服用效果测试,取本发明方法制备的增加人体胶原蛋白及网状纤维的药物一份,其中,按重量份计,包括甘氨酸15份,胶原蛋白肽10份,玉米糖浆4份,二甲基砜4份,硫酸软骨素5份,果糖硼酸钙6份,透明质酸1.5份,菊花提取物1份,可可干籽提取物1.5份,绿茶精华1份,桑叶提取物1.5份、柠檬酸1份和钠0.5份,其余组分为清水,分别另取市售普通他种同类药物3份,其中本发明药物表示为A组,市售他种同类药物分别表示为对照组1、对照组2和对照组3,随机选取120人为试服对象,每30人一组,分别于服药后的第1个月,第3个月和第6个月进行身体状况的问卷调查,分别从使用者的发质状况,骨骼状况和肌肉状况作为调查目标,并进行评分,满分为10分,各组别药物的得分情况如下表所示;
表一为各药物组别使用后发质状况在不同时间区间的得分情况:
组别 | 1个月 | 3个月 | 6个月 |
对照组1 | 4.67 | 6.21 | 7.79 |
对照组2 | 3.24 | 5.21 | 7.07 |
对照组3 | 3.99 | 5.16 | 6.38 |
A组 | 5.87 | 7.64 | 8.89 |
由表一可知,本发明方法制备的增加人体胶原蛋白及网状纤维的药物较市售他种同类药物在服用后对于发质状况的改善效果优势明显,在长期服用时能够得到有效保持。
表二为各药物组别使用后骨骼状况在不同时间区间的得分情况:
组别 | 1个月 | 3个月 | 6个月 |
对照组1 | 5.65 | 6.63 | 8.04 |
对照组2 | 5.33 | 6.76 | 7.94 |
对照组3 | 4.00 | 5.39 | 6.68 |
A组 | 6.62 | 7.88 | 9.21 |
由表二可知,本发明方法制备的增加人体胶原蛋白及网状纤维的药物在服用三个月后对于骨骼的保护效果尤为突出,相对于其他药物,本方明药物在使用后见效更快,具备推广优势。
表三为各药物组别使用后肌肉状况在不同时间区间的得分情况:
组别 | 1个月 | 3个月 | 6个月 |
对照组1 | 3.31 | 4.54 | 6.18 |
对照组2 | 5.88 | 6.20 | 6.74 |
对照组3 | 4.98 | 4.99 | 7.04 |
A组 | 5.85 | 7.37 | 9.32 |
由表三可知,本发明方法制备的增加人体胶原蛋白及网状纤维的药物较市售他种同类药物在服用后对于肌肉状况的改善效果同样明显,能够有效促进生长激素分泌以及肌肉生长,有利于身材的保持,适用于各类人群。
在本说明书的描述中,参考术语“一个实施例”、“示例”、“具体示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
以上公开的本发明优选实施例只是用于帮助阐述本发明。优选实施例并没有详尽叙述所有的细节,也不限制该发明仅为所述的具体实施方式。显然,根据本说明书的内容,可作很多的修改和变化。本说明书选取并具体描述这些实施例,是为了更好地解释本发明的原理和实际应用,从而使所属技术领域技术人员能很好地理解和利用本发明。本发明仅受权利要求书及其全部范围和等效物的限制。
Claims (6)
1.用于增加人体胶原蛋白及网状纤维的药物的制备方法,其特征在于:包括如下步骤:
步骤一:以甘氨酸和胶原蛋白肽为基底原料,依次加入玉米糖浆,二甲基砜,硫酸软骨素和果糖硼酸钙进行预混合,混合时长为4-6min,得到混合物;
步骤二:对上述混合物再依次加入菊花提取物,可可干籽提取物,桑叶提取物、绿茶精华和水,继续搅拌,搅拌时长为8-12min,得到混合溶液;
步骤三:对步骤二中的混合溶液继续加入透明质酸,柠檬酸和钠,搅拌后得到药物溶液;
步骤四:对上述药物溶液进行入模压制,得到所需药物规格和形状;
步骤五:对上述入模的药物溶液进行干燥,干燥温度为75-80℃,干燥时长为25-35min,使其含水率不高于5%;
步骤六:脱模包装后得到所需药物。
2.根据权利要求1所述的用于增加人体胶原蛋白及网状纤维的药物的制备方法,其特征在于:步骤一中各原料的使用含量按重量份计,包括甘氨酸30份,胶原蛋白肽20份,玉米糖浆8份,二甲基砜8份,硫酸软骨素10份和果糖硼酸钙12份。
3.根据权利要求1所述的用于增加人体胶原蛋白及网状纤维的药物的制备方法,其特征在于:步骤二中各原料的使用含量按重量份计,包括菊花提取物2份,可可干籽提取物3份,桑叶提取物3份和绿茶精华2份,其余组分为水。
4.根据权利要求1所述的用于增加人体胶原蛋白及网状纤维的药物的制备方法,其特征在于:步骤三中各原料的使用含量按重量份计,包括透明质酸3份,柠檬酸2份和钠1份。
5.根据权利要求1或3所述的用于增加人体胶原蛋白及网状纤维的药物的制备方法,其特征在于,所述绿茶精华的制备方法为:
步骤一:取200g绿茶茶叶,放入清水浸泡,浸泡时长为10-20min,然后取出自然晾干;
步骤二:对上述晾干的绿茶茶叶进行碾碎,得到绿茶末;
步骤三:将步骤二中的绿茶末放入索氏提取器,再次加入1kg清水,将清水煮沸,并在85-90℃的状态下保持1.5h,待水分蒸发,得到含固态混合物;
步骤四:对上述步骤的含固态混合物进行过滤,即得到所需绿茶精华。
6.根据权利要求1或4所述的用于增加人体胶原蛋白及网状纤维的药物的制备方法,其特征在于:所述柠檬酸的制备方法为:
步骤一:取橙汁和柚汁共50g,将其加热至75-85℃,然后静置10-15min;
步骤二:对上述溶液加入15g碳酸钙乳浆,并再次加热至100℃,持续然后静置沉淀15-25min,得到柠檬酸钙;
步骤三:对步骤二得到的柠檬酸钙进行除盐并酸解脱色,使用清水加热清洗,清洗时长为25-30min,清洗温度为85-90℃,然后加入40%浓度硫酸,并继续加热至100℃,加热时长为8-12min;
步骤五:对上述步骤的溶液加入1-2%含量的活性炭混合,持续反应15-25min,并进行干燥5-8min,即得到无色清液;
步骤六:对上述无色清液进行浓缩,使其呈固态,静置后得到柠檬酸结晶;
步骤七:对上述柠檬酸结晶进行干燥,干燥时长为25-35min,继而得到所需柠檬酸。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010828864.8A CN111956790A (zh) | 2020-08-17 | 2020-08-17 | 用于增加人体胶原蛋白及网状纤维的药物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010828864.8A CN111956790A (zh) | 2020-08-17 | 2020-08-17 | 用于增加人体胶原蛋白及网状纤维的药物的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111956790A true CN111956790A (zh) | 2020-11-20 |
Family
ID=73388239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010828864.8A Pending CN111956790A (zh) | 2020-08-17 | 2020-08-17 | 用于增加人体胶原蛋白及网状纤维的药物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111956790A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030152642A1 (en) * | 1999-06-22 | 2003-08-14 | Stone Kevin R. | Cartilage enhancing food supplements and methods of preparing the same |
US20040029774A1 (en) * | 2002-08-06 | 2004-02-12 | Aly Gamay | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies |
JP2005013124A (ja) * | 2003-06-27 | 2005-01-20 | Toyo Shinyaku:Kk | 美容効果を有する食品組成物 |
CN105452269A (zh) * | 2013-06-17 | 2016-03-30 | 尤妮金公司 | 用于关节健康的组合物和方法 |
CN106835317A (zh) * | 2017-02-27 | 2017-06-13 | 合肥中科富华新材料有限公司 | 一种鱼皮胶原自组装成纤维的方法 |
-
2020
- 2020-08-17 CN CN202010828864.8A patent/CN111956790A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030152642A1 (en) * | 1999-06-22 | 2003-08-14 | Stone Kevin R. | Cartilage enhancing food supplements and methods of preparing the same |
US20040029774A1 (en) * | 2002-08-06 | 2004-02-12 | Aly Gamay | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies |
JP2005013124A (ja) * | 2003-06-27 | 2005-01-20 | Toyo Shinyaku:Kk | 美容効果を有する食品組成物 |
CN105452269A (zh) * | 2013-06-17 | 2016-03-30 | 尤妮金公司 | 用于关节健康的组合物和方法 |
CN106835317A (zh) * | 2017-02-27 | 2017-06-13 | 合肥中科富华新材料有限公司 | 一种鱼皮胶原自组装成纤维的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4201172C1 (en) | Pellets contg. Aloe vera extract - useful, e.g. as antiinflammatory of antibiotic agents, or for treating gastric ulcers | |
CN107184961A (zh) | 一种活性细胞修复剂及其制备方法 | |
CN115381733A (zh) | 一种促进胶原蛋白作用的抗衰老组合物及其应用 | |
EP1295538A2 (de) | Verkapselte Johannisbrotfasern mit verbesserten Produkteigenschaften, Verfahren zu ihrer Herstellung und ihre Anwendung | |
CN112587648A (zh) | 一种防治糖尿病的苦瓜肽组合物及其制备方法 | |
CN111956790A (zh) | 用于增加人体胶原蛋白及网状纤维的药物的制备方法 | |
EP3357352A1 (de) | Zusammensetzung mit aminosäuren | |
CN114365850A (zh) | 一种具有改善软骨健康的多肽组合物及其制备方法 | |
KR20210012979A (ko) | 레반-단백질 나노복합체 및 이의 용도 | |
KR101659927B1 (ko) | 본초의 약효 증대방법, 면역증강용 발효 키토산의 제조방법 및 그 이용 | |
CN114452360B (zh) | 一种小雨燕窝修护滋养凝胶及制备方法 | |
KR100476731B1 (ko) | 국소 도포제 및 환약으로 된 발모제의 제조방법 | |
CN105597081A (zh) | 一种用于降低高血压的药物 | |
CN114158734A (zh) | 一种用于预防或改善黄疸的组合物及其应用 | |
CN110559429B (zh) | 一种蜗牛酶鼻炎膏及其制备方法 | |
CN114366775A (zh) | 一种护目营养液 | |
CN111700223A (zh) | 一种香椿鹅蛋面 | |
AT392003B (de) | Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat | |
CN109453104A (zh) | 淡斑爽肤精华液及其制备工艺 | |
KR102397639B1 (ko) | 단풍취 추출 분말을 이용한 껌의 제조방법 | |
CN109170174A (zh) | 一种鸡饲料添加剂及其应用、鸡饲料 | |
CN108324668A (zh) | 一种由山茶油和蜂蜜组成的润肤油 | |
CN109464453B (zh) | 芦荟纯酰素在制备防治肺纤维化药物中的应用 | |
EP0804152A1 (de) | Lactulose-pastillen | |
CN109350732B (zh) | 一种无糖蜜丸及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |